A Multi-Cohort Phase Ib Trial of Rituximab in Combination with Immunotherapy Doublets in Relapsed/Refractory Follicular Lymphoma

By
lbeveridge
-
0
87
Researchers conducted a Phase Ib trial testing time-limited therapy with different immunotherapy doublets targeting 4-1BB, OX-40, and PD-L1 in combination with rituximab among patients with relapsed/refractory grade 1–3A FL.
[Annals Of Hematology]
Abstract